www.drugs.com/medical-answers/what-vx-548-3576627/
.... Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review. US Food & Drug Administration. 6 Dec 2023. Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain. Jan 30, 2024. Vertex. Read next What is low dose naltrexone...